Psychiatry

  • Research Faculty

  • Show All

    Division Head

    A photo of Michael Sorter.

    Michael T. Sorter, MD Director, Division of Psychiatry

    is a clinical and administrative psychiatrist whose career focus has been the expansion, improvement, and administration of clinical psychiatric services for children and families. In 2013, Cincinnati Children’s Hospital Medical Center is the largest Pediatric Hospital Child Psychiatric Service in the country that offers a full continuum of care, including inpatient, residential, and partial hospital.

    513-636-8336
    michael.sorter@cchmc.org

    Michael T. Sorter, MD

    Director, Division of Psychiatry

    Academic Information

    Professor, UC Department of Pediatrics

    Phone: 513-636-8336

    Email: michael.sorter@cchmc.org

    Show All

    Specialties

    Training; pediatric psychopharmacology; residential and inpatient treatment of adolescents; mental retardation; developmental disorders

    Education and Training

    BS: Zoology, The Ohio State University, Columbus, OH, 1981.

    MD: University of Cincinnati, Cincinnati, Ohio, 1985.

    Residency: Psychiatry, University of Cincinnati, Cincinnati, OH, 1988.

    Fellowship: Child Psychiatry, University of Cincinnati, Cincinnati, OH, 1990.

    Certification: General Psychiatry, American Board of Psychiatry and Neurology, 1992; Child and Adolescent Psychiatry, American Board of Psychiatry and Neurology, 1993.

    Publications

    View PubMed Publications

    Grants

    Trauma Screening in Schools Planning Grant. Principal Investigator. Greater Cincinnati Health Foundation. Feb 2013.

    Faculty

    A photo of Drew Barzman.

    Drew H. Barzman, MD Director, Child and Adolescent Forensic Psychiatry Service

    and his child forensic research team developed the Brief Rating of Aggression by Children and Adolescents (BRACHA), a reliable instrument for predicting aggression and violence in the hospital. His team has also studied salivary biomarkers associated with future aggression by children. Currently, his team is combining fMRI, salivary biomarkers and the BRACHA to better predict pediatric aggression and violence. In addition, his child forensic team has developed one the largest databases on pediatric aggression and violence for analysis.

    513-636-8727
    drew.barzman@cchmc.org

    Drew H. Barzman, MD

    Director, Child and Adolescent Forensic Psychiatry Service

    Academic Information

    Assistant Professor, N/A

    Assistant Professor, UC Department of Psychiatry and Behavioral Neuroscience

    Phone: 513-636-8727

    Fax: 513-636-4788

    Email: drew.barzman@cchmc.org

    Show All

    Specialties

    Clinical Interests

    Child and adolescent forensic psychiatry

    Research Interests

    Child and adolescent forensic psychiatry; prevention of violence in youth; neuroimaging in children and adolescents; genetics; pediatric clinical trials

    Biography

    Dr. Barzman’s most significant professional achievements include helping children and families, research, and mentoring undergraduate and graduate students.

    Education and Training

    MD: Buffalo, School of Medicine, State University of New York, 1997.

    Residency: Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, 1997-2001.

    Fellowship: Forensic Fellow, Department of Psychiatry, University of Cincinnati, Cincinnati, OH, 2001-2002.

    Fellowship: Child and Adolescent Psychiatry, Cincinnati Children's Hospital Medical Center, 2002-2004.

    Licensure: State of Ohio Medical License, 2001.

    Certifications: Psychiatry (2002), Forensic Psychiatry (2003), Child and Adolescent Psychiatry (2004); Dr. Barzman successfully passed the Maintenance of Certification Examination in Psychiatry, Forensic Psychiatry, and Child and Adolescent Psychiatry in April 2011. 

    Recertification: Passed Modular Examination for Maintenance of Certification in the Specialty of Psychiatry and the Subspecialties of Forensic Psychiatry and Child and Adolescent Psychiatry in April 2011.

    Publications

    View PubMed Publications

    Grants

    Identification of Genetic Predispositions for Bipolar Disorder in Children. Co-Principal Investigator. Oxley Foundation. Dec 2011 - Nov 2014.
    A photo of Sergio Delgado.

    Sergio V. Delgado, MD Medical Director of Outpatient Services, Division of Child and Adolescent Psychiatry

    is a clinical investigator who has clinical trial research programs in depression in the Division of Psychiatry.

    513-636-4788
    sergio.delgado@cchmc.org

    Sergio V. Delgado, MD

    Medical Director of Outpatient Services, Division of Child and Adolescent Psychiatry

    Chair, Child Psychoanalytic Program

    Academic Information

    Professor, N/A

    Professor, UC Department of Psychiatry and Behavioral Neuroscience

    Phone: 513-636-4788

    Email: sergio.delgado@cchmc.org

    Show All

    Specialties

    Learning disorders; ADHD; psychotherapy

    Biography

    Dr. Delgado is a professor in the Division of Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center and the University of Cincinnati. He is the medical director of outpatient services and director of psychotherapy services in the Division of Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center.

    His research involves the pharmacological treatment of children and adolescents with ADHD, bipolar disorders and depression.

    He also is a supervising and training adult and child analyst at the Cincinnati Psychoanalytic Institute.

    Education and Training

    MD: Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, 1981.

    Residency: Karl Menninger School of Psychiatry, Topeka, KS.

    Fellowship: Child and Adolescent Psychiatry, Karl Menninger School of Psychiatry, Topeka, KS.

    Certifications: Psychiatry, 1988; Child and Adolescent Psychiatry, 1990; Psychoanalysis, 1994; Child and Adolescent Psychoanalysis, 1994.

    Publications

    View PubMed Publications
    A photo of Craig Erickson.

    Craig A. Erickson, MD

    conducts translational research focused on targeted treatment development in autism spectrum disorders and fragile X syndrome.
    Visit the Erickson-Wink Lab web site.

    513-636-4611
    craig.erickson@cchmc.org

    Craig A. Erickson, MD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4611

    Email: craig.erickson@cchmc.org

    Show All

    Specialties

    Fragile X syndrome; autism spectrum disorders

    Visit the Erickson-Wink Lab web site.

    Education and Training

    MD: University of Cincinnati.

    Residency: Psychiatry, Indiana University; Child and Adolescent Psychiatry, Indiana University.

    Publications

    View PubMed Publications

    Grants

    Extracellular Signal-Related Kinase Biomarker Development in Autistic Disorder. Principal Investigator. Simons Research Foundation. Sep 2012-Aug 2014.

    Autism Speaks Treatment Award. Principal Investigator. Autism Speaks. Jan 2013-Dec2015.

    No photo available

    Elana Harris, MD, PhD

    is a neuroscientist with basic and translational interest in the neurophysiological underpinnings of obsessive-compulsive disorder. She uses magnetoencephalography to examine the frequency of oscillations in various components of the circuitry that supports this condition. Predicting treatment outcome is another focus of the lab.

    513-636-2100
    elana.harris@cchmc.org

    Elana Harris, MD, PhD

    Academic Information

    Assistant Professor, N/A

    Assistant Professor, UC Department of Psychiatry and Behavioral Neuroscience

    Phone: 513-636-2100

    Email: elana.harris@cchmc.org

    Show All

    Specialties

    Conditions: anxiety disorders; obsessive compulsive disorder; Tourette syndrome; trichotillomania

    Treatment modalities: habit reversal therapy; pharmacotherapy

    Education and Training

    MD: State University of New York, Downstate Medical Center.

    PhD: Neural and Behavioral Science; State University of New York, Downstate Medical Center.

    Internship: Pediatrics, Winthrop University Hospital, Mineola, NY.

    Residency: Psychiatry, Johns Hopkins Hospital, Baltimore, MD.

    Fellowship: Child and Adolescent Psychiatry, Johns Hopkins Hospital, Baltimore, MD.

    Publications

    Grants

    The Frequency of Oscillations in OCD. Principal Investigator. International OCD Foundation.

    DefaultUserSmall

    Tzipi Horowitz-Kraus, PhD Program Director, Reading and Literacy Discovery Center

    focuses on the role of executive functions in oral and written language in typically developing children and in children with a variety of reading disorders (dyslexia, ADHD, psychiatric disorders, Epilepsy, etc.). Using fMRI analysis methods, she characterizes the neural circuits related to executive functions, oral language and reading in children and examines the effect of different interventions on these neural circuits.

    Visit Dr. Horowitz-Kraus' lab web site.

    513-803-5162
    tzipi.horowitz-kraus@cchmc.org

    Tzipi Horowitz-Kraus, PhD

    Program Director, Reading and Literacy Discovery Center

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-803-5162

    Email: tzipi.horowitz-kraus@cchmc.org

    Show All

    Specialties

    Research

    Neuroimaging: written language; oral language development

    Visit Dr. Horowitz-Kraus' lab web site.

    Biography

    Dr. Horowitz-Kraus' lab has found that reading intervention results in neural circuits related to both normalization and compensation in children with dyslexia. They have also highlighted the importance of the right hemisphere in reading comprehension both in children (7-9 years) and in adolescents (18 years).

    Education and Training

    PhD: University of Haifa, Haifa, Israel.

    Publications

    View PubMed Publications
    A photo of Brian Kurtz.

    Brian P. Kurtz, MD Attending Psychiatrist, Division of Child and Adolescent Psychiatry

    is the director of the Psychiatry Consultation-Liaison Service at Cincinnati Children's. Prior to joining the faculty in 2011, he was the director of the Pediatric Consultation-Liaison Psychiatry Program at Tufts Medical Center in Boston, MA.

    513-636-4788
    brian.kurtz@cchmc.org

    Brian P. Kurtz, MD

    Attending Psychiatrist, Division of Child and Adolescent Psychiatry

    Academic Information

    Assistant Professor, N/A

    Assistant Professor, UC Department of Psychiatry and Behavioral Neuroscience

    Phone: 513-636-4788

    Email: brian.kurtz@cchmc.org

    Show All

    Specialties

    Consultation-liaison psychiatry; psychiatry with medical comorbidity

    Education and Training

    MD: The Ohio State University, Columbus, OH, 2004.

    Internship: Pediatrics, Children’s National Medical Center, Washington, DC, 2005.

    Residency: Psychiatry, The Cambridge Hospital, Cambridge, MA, 2008.

    Fellowship: Child and Adolescent Psychiatry, Massachusetts General Hospital/McLean Hospital, Boston, MA, 2010. 

    Certification: Psychiatry, 2008; Child and Adolescent Psychiatry, 2010.

    Publications

    wink-logan-thumb

    Logan K. Wink, MD

    is an assistant professor of Clinical Psychiatry who specializes in Autism Spectrum Disorders and related developmental disabilities. Her clinical research include descriptive studies and drug trials in Angelman syndrome and Autism Spectrum Disorders.
    Visit the Erickson/Wink Lab website.

    513-636-4611
    logan.wink@cchmc.org

    Logan K. Wink, MD

    Academic Information

    Assistant Professor, UC Department of Pediatrics

    Phone: 513-636-4611

    Email: logan.wink@cchmc.org

    Show All

    Specialties

    Autism spectrum disorders; Angelman syndrome.

    Visit the Erickson/Wink lab website.

    Biography

    Dr. Logan Wink is an assistant professor of Clinical Psychiatry at Cincinnati Children’s Hospital Medical Center. Dr. Wink is a child and adolescent psychiatrist involved in clinical research and clinical care of individuals with developmental disabilities, including Autism Spectrum Disorders and Angelman Syndrome. 

    Her primary research focus is improving clinical care of individuals with developmental disabilities through better understanding the pathology of these disorders and improving pharmacologic treatment.

    Education and Training

    MD: Indiana University School of Medicine, Indianapolis, IN.

    Residency: Psychiatry, Indiana University School of Medicine, Indianapolis, IN.

    Fellowship: Child Psychiatry, Indiana University School of Medicine, Indianapolis, IN.

    Fellowship: Autism and Developmental Disabilities, Indiana University School of Medicine, Indianapolis, IN.

    Publications

    View PubMed Publications.

    Grants

    Characterization of Angelman Syndrome. Site Investigator. National Institutes of Health. Jan 2006 - Jun 2016.

    A Randomized, Placebo-Controlled Trial of D-Cycloserine for the Enhancement of Social Skills Training in Pervasive Developmental Disorders. Co-Investigator. Department of Defense. Mar 2010 - Feb 2014.

    A Trial of Levodopa in Angelman Syndrome. Site Investigator. United States Food and Drug Administration Office of Orphan Products Development. Jul 2010 - Jun 2014.

    Extracellular Signal-Related Kinase Biomarker Development in Autistic Disorder. Co-Investigator. Simons Research Foundation SFARI PILOT AWARD. Sep 2012 - Aug 2014.

    A randomized, double blind, placebo-controlled crossover study to evaluate riluzole for treatment of drug-refractory irritability in autism spectrum disorder. Primary Investigator. Pilot Research Award, Center for Clinical and Translational Science and Training. University of Cincinnati Academic Health Center. Jul 2013 - Jun 2014.

    Acamprosate in Autistic DisorderCo-Investigator. Autism Speaks. Jan 2013 - Dec 2015. 

    Acamprosate in Fragile X SyndromeCo-Investigator. John Merck Fund Translational Research Program Award. Jan 2013 - Dec 2016. 

    FRAGILE X CLINICAL AND RESEARCH CONSORTIUM FORWARD REGISTRY AND DATABASECo-Investigator. National Fragile X Foundation/Centers for Disease Control. Sep 2012 - Dec 2014.

    A Double Blind, Placebo-Controlled Phase III trial of evaluating the Efficacy, Safety, and Tolerability of STX209 in the Treatment of Fragile X Syndrome in youthCo-Investigator. Seaside Therapeutics. Oct 2012 - Oct 2013.

    A Double Blind, Placebo-Controlled Phase II trial of evaluating the Efficacy, Safety, and Tolerability of RO4917523 in the Treatment of Fragile X Syndrome in adolescents and adultsCo-Investigator. F. Hoffmann LaRoche. Sep 2012 - Sep 2013. 

    AUTISM SPECTRUM DISORDER GENE EXPRESSION ANALYSIS (STORY) STUDYPrimary Investigator. SynapDx. CCHMC Site.